Navigation Links
CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
Date:4/1/2008

LAS VEGAS, April 1, 2008 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has appointed Nabil Dib, M.D., M.Sc., F.A.C.C., as the Principal Investigator for its Phase II clinical trial in patients with severe coronary heart disease.

Dr. Dib is currently the Director of Cardiovascular Research at Catholic Healthcare West's Chandler Regional Medical Center and Mercy Gilbert Medical Center in Arizona, as well as the Assistant Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy at the University of California, San Diego. He is also President of the International Society for Cardiovascular Translational Research, La Jolla, Calif., and an international expert on the treatment of heart failure and coronary artery disease. Dr. Dib has extensive experience directing clinical trials, particularly in the arena of examining agents which stimulate the growth of new blood vessels in a damaged heart.

In previous clinical studies, Dr. Dib has pioneered the use of the NOGA(R) XP mapping system and the MyoStar(TM) injection catheter. These two devices will be used in CVBT's Phase II heart trial, in which the potent angiogenic protein human Fibroblast Growth Factor -1 (FGF-1) will be injected into patients' hearts. Dr. Dib serves as the principal trainer for all interventional cardiologists who wish to receive training on the NOGA XP system or MyoStar injection catheter, and will work closely with the other clinical investigators in CVBT's Phase II heart trial to ensure the safe and accurate injection of FGF-1 into the heart.

"We are extremely excited to welcome a cardiologist and clinical researcher of Dr. Dib's caliber to lead our Phase II heart study," said Thomas J. Stegmann, M.D., co-founder and co-president of CVBT. "His expertise with the NOGA XP and MyoStar devices, and his strong relationships with leading interventional cardiologists throughout the world will be invaluable to our clinical effort to establish FGF-1 as the treatment of choice for severe angina and coronary heart disease."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials underway in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional trial is also being conducted in patients with chronic back pain who may have perfusion defects to their spine.

About Catholic Healthcare West

Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and one of the largest not-for-profit hospital providers in the West. Founded in 1986, the CHW network of more than 8,500 physicians and approximately 50,000 employees serve a population spanning 22 million people at 43 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In fiscal year 2007, CHW provided $922 million in charity care, community benefits, and unreimbursed patient care. CHW facilities in Arizona include Chandler Regional Medical Center, Mercy Gilbert Medical Center, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, CHW Urgent Cares in Ahwatukee, Gilbert and Queen Creek, Sun Lakes Laboratory, Warner Outpatient Surgery and the Arizona Orthopedic Surgical Hospital. For more information, please visit our Website at http://www.chwHEALTH.org.

About Chandler Regional Medical Center

Chandler Regional Medical Center is a 225-bed, acute-care, non-for-profit provider of emergency care, maternal child services, cardiovascular services, wound healing, cancer treatment, diabetes treatment, and diagnostic services. It is located at 475 S. Dobson Road (corner of Dobson Road and Frye Road) in Chandler. For more information, please visit http://www.chandlerregional.org or call (480) 728-3000. Chandler Regional Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-3424. For information on physician referrals or community classes and support groups, please contact the ResourceLink toll-free at 1.877.728.5414 or resourcelink@chw.edu.

About Mercy Gilbert Medical Center

Mercy Gilbert Medical Center is located at the intersection of Val Vista Drive and Loop 202 (south of Pecos Road and east of Val Vista Drive). Mercy Gilbert Medical Center is a four-story, full-service acute-care facility with 182 beds. For more information, please visit http://www.mercygilbert.org or call (480) 728-8000. Mercy Gilbert Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-8396. For information on physician referrals or community classes and support groups, please contact the ResourceLink toll-free at 1.877.728.5414 or resourcelink@chw.edu.

CardioVascular BioTherapeutics, Inc.

Allison Lipson, (702) 839-7200

alipson@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. West Pharmaceutical Services, Inc. Appoints New Director
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
6. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
7. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Potrero Medical, Inc., the developer of the Accuryn™ ... of George M. Rapier, III , MD, to its ... , WellMed is one of the nation,s largest physician owned ... in Texas and Florida ... own internal medicine practice, he has been instrumental to the ...
(Date:2/11/2016)... Feb. 11, 2016 AAIPharma Services Corp./Cambridge ... custom manufacturing and development services for the pharmaceutical ... capabilities and capacity in its Charleston, ... has driven several recent investments. ... one filling line with small-scale lyophilization. The site ...
(Date:2/11/2016)... , Feb. 11, 2016 Wearable posture tracker, ALEX , has taken Kickstarter by ... and just seven days left to go, ALEX is said to be delivered to backers starting May ... ... ... Created by ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking one of the ... into osteopathic graduate medical education positions across the country. Of the 103 student-doctors ...
(Date:2/11/2016)... ... 2016 , ... Image One USA veteran franchise owner Maria Bogacki ... buildings of Nashville that will benefit. , “I’ve enjoyed being a part of the ... was no question that I would bring my business with me,” Bogacki said. “The ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... ISLAND, Australia (PRWEB) , ... February 11, 2016 ... ... full potential ?" motivational speaker, trainer and author Ray Clarke poses a question ... personal fulfillment . In his book, "Being in the Being" (published by ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein ... resource, Infusion Therapy Standards of Practice, to include vascular visualization as a standard ... estimated 85% share of the market, facilitates adherence to this standard with its ...
Breaking Medicine News(10 mins):